Dapagliflozin Faces Ominous Prospect Of New Trials

By Emily Hayes / Email the Author / “The Pink Sheet” DAILY Jan. 19, 2012
Word Count: 1006 / Article # 14120119001

Executive Summary

FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 1006-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Dapagliflozin Faces Ominous Prospect Of New Trials

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” DAILY will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Dapagliflozin Faces Ominous Prospect Of New Trials

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 13

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article